Home › Trial NCT07321652
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Trial IDNCT07321652
- StatusRecruiting
- PhasePhase 3
- Study typeInterventional
- SponsorAlliance for Clinical Trials in Oncology
- Enrollment466
- Start date2026-04-30
- ConditionsChronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.